{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:04:58Z","timestamp":1790330698596,"version":"4.1.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION trial demonstrated that [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival (rPFS) establishing PSMA-targeted RLT as a key treatment option in advanced disease. Prostate-specific Membrane Antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) plays a central role in patient selection, treatment monitoring, and prognostic stratification, thereby supporting a precision oncology approach. More recently, the clinical development of PSMA-targeted radioligand therapy (RLT) has expanded in several directions, including its use in earlier disease stage, such as metastatic hormone-sensitive prostate cancer (mHSPC), and in the neoadjuvant and oligometastatic settings, as well as its integration into multimodal treatment strategies. These include combination approaches with androgen receptor pathway inhibitors (ARPIs), chemotherapy, immunotherapy, and radiation therapy. This review provides a comprehensive overview of the major developments in the field, including advances in molecular imaging, emerging therapeutic indications, combination approaches, and future directions in PSMA-targeted theranostics according to recent clinical trial data. Collectively, these developments highlight the evolving role of beta-emitting RLT across the prostate cancer disease.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1925228","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:33:46Z","timestamp":1790328826000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["PSMA-targeted radioligand therapy with beta emitters in prostate cancer: current evidence, emerging indications, combination strategies, and future directions"],"prefix":"10.3389","volume":"13","author":[{"given":"Hiba","family":"Noamen","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bekkhoucha","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bernard Tessier","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khali","family":"Trabelsi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Borsali","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Naoun","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Rey-Cardenas","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Daverio","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Flippot","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Pobel","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lison","family":"Ferreol","sequence":"additional","affiliation":[{"name":"Radiopharmacy Unit, Pharmacy Department, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Patrikidou","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Barraud","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Uliano","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Megherbi","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Terlizzi","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Dipalma","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[{"name":"Department of Cancer Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"Deandreis","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Gustave Roussy, Paris Saclay University","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"74","author":"Sung","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of [177Lu]-labeled PSMA-targeted radioligand therapy ([177Lu]-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"[177lu]lu-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-20-0580","article-title":"A prospective trial of 68Ga-PSMA and 18F-FDG PET\/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration","volume":"26","author":"Wang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[177lu]lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00519-6","article-title":"PSMA and FDG PET as predictive and prognostic biomarkers in patients given [177Lu]lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomized, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific membrane antigen reporting and data system version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1007\/s00261-024-04738-2","article-title":"PSMA-RADS to improve evaluation and management of prostate cancer","volume":"50","author":"Rafiei Alavi","year":"2025","journal-title":"Abdom Radiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/jnumed.121.263072","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1200\/JCO-25-02834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from the prostate cancer working group 4","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.eururo.2025.08.005","article-title":"SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a delphi analysis","volume":"89","author":"Herrmann","year":"2026","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomized, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"[177lu]lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-na\u00efve patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomized, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1483953","DOI":"10.3389\/fonc.2024.1483953","article-title":"Initial clinical experience with [177Lu]lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial","volume":"14","author":"Hansen","year":"2025","journal-title":"Front Oncol"},{"key":"B21","year":""},{"key":"B22","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/j.ijrobp.2024.07.008","article-title":"A phase 2\/3 study of [177Lu]lu-TLX591 plus standard of care versus standard of care alone in patients with metastatic castration-resistant prostate cancer (ProstACT GLOBAL)","volume":"120","author":"Sartor","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B23","doi-asserted-by":"publisher","first-page":"TPS210","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS210","article-title":"PSMAddition: a phase 3 trial to compare treatment with [177Lu]lu-PSMA-617 plus standard of care versus standard of care alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"40","author":"Sartor","year":"2022","journal-title":"J Clin Oncol"},{"key":"B24","author":"Tagawa","year":""},{"key":"B25","author":"Fizazi","year":""},{"key":"B26","year":""},{"key":"B27","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00384-7","article-title":"Sequential [177Lu]lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomized, phase 2 study","volume":"25","author":"Azad","year":"2024","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1470-2045(25)00762-4","article-title":"[177lu]lu-PSMA-617 in oligometastatic hormone-sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study","volume":"27","author":"Priv\u00e9","year":"2026","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bju.15988","article-title":"LUNAR: a randomized phase 2 study of [177Lu]lu-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol)","volume":"132","author":"Ma","year":"2023","journal-title":"BJU Int"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1200\/JCO-25-01553","article-title":"[177lu]lu-prostate-specific membrane antigen neoadjuvant to stereotactic ablative radiotherapy for oligorecurrent prostate cancer (LUNAR): an open-label, randomized, controlled, phase II study","volume":"43","author":"Kishan","year":"2025","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","article-title":"Administering [177Lu]lu-PSMA-617 prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy): a single-centre, single-arm, phase 1\/2 study","volume":"85","author":"Eapen","year":"2024","journal-title":"Eur Urol"},{"key":"B32","year":""},{"key":"B33","year":""},{"key":"B34","year":""},{"key":"B35","year":""},{"key":"B36","year":""},{"key":"B37","year":""},{"key":"B38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-019-04529-8","article-title":"Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients","volume":"47","author":"Vaz","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177lu]lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomized, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2967\/jnumed.125.269252","article-title":"Prognostic value of 3-month PSMA-PET total tumor volume in ENZA-p: a randomized phase 2 trial of [177Lu]lu-PSMA-617 plus enzalutamide versus enzalutamide in metastatic castration-resistant prostate cancer","volume":"67","author":"Subramaniam","year":"2026","journal-title":"J Nucl Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/CAD.0000000000000055","article-title":"Taxanes as radiosensitizers","volume":"25","author":"Golden","year":"2014","journal-title":"Anticancer Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"848.e9","DOI":"10.1016\/j.urolonc.2020.05.028","article-title":"Phase 1 trial of docetaxel plus [177Lu]lu-J591 (lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody) for metastatic castration-resistant prostate cancer","volume":"38","author":"Batra","year":"2020","journal-title":"Urol Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2967\/jnumed.124.269252","article-title":"Clinical trial protocol for LuCAB: a phase 1\u20132 trial evaluating cabazitaxel in combination with [177Lu]lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"66","author":"Kostos","year":"2025","journal-title":"J Nucl Med"},{"key":"B44","year":""},{"key":"B45","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.121.262552","article-title":"[177lu]lu-PSMA-617 and idronoxil in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): patient outcomes and predictors of treatment response in a phase 1\u20132 trial","volume":"63","author":"Pathmanandavel","year":"2022","journal-title":"J Nucl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/pharmaceutics15122761","article-title":"DNA damage by radiopharmaceuticals and mechanisms of cellular repair","volume":"15","author":"Monfared Y","year":"2023","journal-title":"Pharmaceutics"},{"key":"B47","doi-asserted-by":"crossref","first-page":"2391P","DOI":"10.1016\/j.annonc.2025.08.3007","article-title":"LuPARP: phase I trial of [177Lu]lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)","volume":"36","author":"Sandhu","year":"2025","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e29715","DOI":"10.1097\/MD.0000000000029715","article-title":"The efficacy and safety of immune checkpoint inhibitors in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"101","author":"Wang","year":"2022","journal-title":"Medicine (Baltimore"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.2967\/jnumed.125.270317","article-title":"Combining PSMA-targeted radiopharmaceutical therapy with immunotherapy","volume":"66","author":"Altunay","year":"2025","journal-title":"J Nucl Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017","article-title":"PRINCE: phase 1 trial of [177Lu]lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"40","author":"Sandhu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"[161tb]tb for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.2967\/jnumed.123.265509","article-title":"Membrane and nuclear absorbed doses from [177Lu]lu and [161Tb]tb in tumor clusters: effect of cellular heterogeneity and potential benefit of dual targeting\u2014a monte carlo study","volume":"64","author":"Larouze","year":"2023","journal-title":"J Nucl Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of [161Tb]tb-PSMA-I&T dual beta-auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\u20132 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.7150\/thno.92273","article-title":"[161tb]tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [177Lu]lu-PSMA-617","volume":"14","author":"Schaefer-Schuler","year":"2024","journal-title":"Theranostics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.7150\/thno.115831","article-title":"Pilot experience of [161Tb]tb-PSMA-617 RLT in mCRPC patients after conventional PSMA RLT within a prospective registry","volume":"15","author":"Rosar","year":"2025","journal-title":"Theranostics"},{"key":"B56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov"},{"key":"B58","year":""},{"key":"B59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.71004\/rss.026.v5.i1.50","article-title":"In silico investigation of the interactions of piflufolastat F-18 and flotufolastat F-18 radiopharmaceuticals with biological targets relevant to prostate cancer diagnosis","volume":"5","author":"Mabikayi","year":"2026","journal-title":"Rev Sci Sant"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1925228\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:33:47Z","timestamp":1790328827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1925228\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":59,"alternative-id":["10.3389\/fmed.2026.1925228"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1925228","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1925228"}}